论文部分内容阅读
HSP90作为一种热休克蛋白参与调控蛋白质的正确折叠、装配和水解等多种生理过程,其在肿瘤组织中异常表达与活化,与恶性肿瘤的发生发展密切相关,是肿瘤药物研发的重要靶标,目前已有多个HSP90抑制剂进入临床研究。近年来研究发现,HSP90在调控机体固有性免疫和适应性免疫反应中也发挥着重要的作用,包括抗原呈递、T细胞、NK细胞活化和DC(树突状细胞)的成熟,以及肿瘤微环境的免疫抑制等。抑制HSP90导致免疫抑制和免疫激活双重反应,因此,HSP90在机体免疫中作用复杂,有待人们进一步研究。本文主要综述了HSP90及其抑制剂与肿瘤免疫之间的联系,为今后相关研究人员的工作提供参考。
As a heat shock protein, HSP90 is involved in the regulation of the proper folding, assembly and hydrolysis of proteins, and its abnormal expression and activation in tumor tissues. It is closely related to the occurrence and development of malignant tumors and is an important target for tumor drug development. Several HSP90 inhibitors are currently in clinical trials. Recent studies have found that HSP90 also plays an important role in the regulation of innate and adaptive immune responses in the body, including antigen presentation, activation of T cells and NK cells, and maturation of DCs (dendritic cells), as well as tumor microenvironment Immune suppression and so on. Inhibition of HSP90 leads to dual immunosuppression and immune activation, therefore, HSP90 complex role in the body immunity, pending further study. This review summarizes the relationship between HSP90 and its inhibitors and tumor immunity and provides reference for the future researchers.